Adis Journals

_

A premier collection of drug-focused medical journals and newsletters across the medical, biomedical and pharmacological areas

Adis is a reputable and independent publisher providing unique and valued content to its readers.  The Adis journals portfolio host a set of unique titles with highlights setting them apart from their competitors.  Adis journals are all peer-reviewed, and many with expert in-house Editors-in-Chief overseeing the quality of the articles being published.

Adis Journal archive

Features and Benefits

·        Access to clinically relevant and definitive research and reviews on a variety of subjects

·        All peer-reviewed, and many with expert in-house Editors-in-Chief

·        The Adis journals portfolio is an invaluable resource and receiving high number of downloads every year

·        Various options and services for those seeking to publish research on drugs or other related areas

·        Efficient publication process with high ethical standards

Adis Journals brochure
Adis Journals brochure
(PDF, 2.49 MB)

Journal Disciplines + Highlights

Adis newsletter reactions 40278
targeted oncology 11523
12325
drug safety 40264
Adis newsletter pharmaco 40274
40272

Biomedicine

40259
40290
40291

Pharmacy

40264
40277

Additional information

_

Access Adis journal archives

 An invaluable archival resource for anyone involved in medical research, practice or teaching; drug regulation or reimbursement; or any part of the pharmaceutical industry.

_

Request a Trial

Weitere Informationen auf unserer englischen Webseite

Stay up to date

_
Follow us on Twitter

Here to foster information exchange with the library community

_
Follow us on Facebook

Springer Nature's LibraryZone is a community developed to foster sharing of information with the library community. Enjoy!

_
Connect with us on LinkedIn

Connect with us on LinkedIn and stay up to date with news and development.

_
Sign up for our alerts

News, information on our forthcoming books, author content and discounts.